PFSA

Profusa, Inc. (PFSA) - 10-Q Summary for Period Ended June 30, 2026

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Profusa, Inc., a clinical-stage digital health company developing biointegrated sensors (Lumee Oxygen and Lumee Glucose platforms). The report covers the three and six months ended June 30, 2026. The Company is a smaller reporting company and an emerging growth company. As of August 18, 2026, there were 605,647 shares of common stock outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased 141% to $12.2 million for the six months ended June 30, 2026, compared to $5.1 million in the prior year period. This was driven by a 170% increase in operating expenses to $6.6 million.
• Expense Drivers: Research and Development (R&D) expenses rose 138% to $2.0 million due to increased Contract Research Organization (CRO) and regulatory costs. General and Administrative (G&A) expenses surged 186% to $4.6 million, primarily due to legal, accounting, and professional service fees.
• Non-Cash Fair Value Adjustments: The Company recorded a $5.0 million loss on the change in fair value of convertible notes, compared to $0.3 million in the prior year. This was largely due to the remeasurement of Ascent PIPE Notes and related party notes.
• Financing Costs: Financing costs of $2.5 million were recorded, primarily related to the issuance of Ascent Warrants ($2.2 million) and ELOC share issuances.
• PPP Loan Forgiveness: The Company recognized a $1.4 million gain on the extinguishment of its PPP loan, which was forgiven in February 2026.
• Digital Assets: The Company terminated its Bitcoin treasury strategy, selling 16.51 Bitcoins for $1.2 million, resulting in a $0.3 million realized loss.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern: The filing explicitly states that conditions raise substantial doubt about the Company's ability to continue as a going concern within one year. The Company has a working capital deficit of $27.3 million and expects to incur substantial losses in the foreseeable future.
• Liquidity and Financing: The Company relies on debt and equity financing. It has an Equity Line of Credit (ELOC) with Ascent Partners for up to $100 million (with $86.9 million remaining capacity) and a PIPE facility with $9.8 million available for drawdown. Management estimates near-term capital requirements through June 2027 to be approximately $21.6 million.
• Nasdaq Compliance: The Company was subject to delisting proceedings for failing to meet Minimum Bid Price and Market Value requirements. It received an exception to continue listing on The Nasdaq Capital Market subject to conditions, including a reverse stock split and demonstrating compliance with stockholders' equity requirements by July 31, 2026.
• Reverse Stock Splits: The Company effected three reverse stock splits (1-for-75 in Feb, 1-for-25 in July, and 1-for-4 in August 2026) to regain compliance. All share data in the filing is retroactively adjusted.
• Strategic Transactions:
  • Bio Insights Acquisition: Entered an Asset Purchase Agreement to acquire PanOmics Assay assets for $30 million in Series A Preferred Stock. Closing is subject to conditions and stockholder approval.
  • G3 Vision Labs Option: Entered an option agreement to acquire G3 Vision Labs Inc. (health diagnostics). The option is subject to securing $30 million in financing and other conditions. Consideration included issuance of common stock and Series A Preferred Stock.
• Internal Controls: Management concluded that internal controls over financial reporting were not effective due to material weaknesses in segregation of duties, valuation of financial instruments, and technical accounting expertise.

Investor Verification Checklist

• Going Concern Status: Verify the Company's ability to secure the estimated $21.6 million needed for operations through 2027 given the $27.3 million working capital deficit.
• Nasdaq Listing: Confirm formal confirmation from Nasdaq that the Company has met the conditions for continued listing on The Nasdaq Capital Market.
• Debt Conversion Terms: Review the terms of the Ascent PIPE Notes and related party convertible notes, specifically the conversion prices and the impact of recent reverse stock splits on dilution.
• Acquisition Conditions: Monitor the status of the $30 million financing required to exercise the option to acquire G3 Vision Labs and the closing conditions for the Bio Insights acquisition.
• Regulatory Milestones: Track progress on obtaining a renewed CE Mark for Lumee Oxygen in Europe and FDA clearance for the U.S. market, as commercialization depends on these approvals.
• Internal Controls Remediation: Assess the timeline and plan for remediation of the material weaknesses in internal controls over financial reporting.